Details of the Drug

General Information of Drug (ID: DMUBP9O)

Drug Name
Voglibose
Synonyms
Basen; Glustat; Vocarb; Basen OD; A-71100; AO-128; Basen (TN); Basen (Takeda Chemical Industries); Volix (Ranbaxy labs);Voglibose (JP15/USAN/INN); N-(1,3-Dihydroxyprop-2-yl)valiolamine; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1]
Non-insulin dependent diabetes 5A11 Approved [2]
Gaucher disease 5C56.0Y Investigative [3]
Therapeutic Class
Hypoglycemic Agents
Affected Organisms
Humans and other mammals
ATC Code
A10BF03: Voglibose
A10BF: Alpha glucosidase inhibitors
A10B: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10: DRUGS USED IN DIABETES
A: ALIMENTARY TRACT AND METABOLISM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 267.28
Logarithm of the Partition Coefficient (xlogp) -4.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 8
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 8.17 mgh/L [4]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1.38 mg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2.5 h [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.08 hours [4]
Chemical Identifiers
Formula
C10H21NO7
IUPAC Name
(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
Canonical SMILES
C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
InChI
InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
InChIKey
FZNCGRZWXLXZSZ-CIQUZCHMSA-N
Cross-matching ID
PubChem CID
444020
ChEBI ID
CHEBI:32300
CAS Number
83480-29-9
UNII
S77P977AG8
DrugBank ID
DB04878
TTD ID
D04ZTY
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Intestinal maltase-glucoamylase (MGAM) TTXWASR MGA_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Intestinal maltase-glucoamylase (MGAM) DTT MGAM 4.59E-01 -0.02 -0.24
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013 Sep 2;6:317-25.
3 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
4 Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin. Int J Clin Pharmacol Ther. 2015 Feb;53(2):147-53. doi: 10.5414/CP202197.
5 Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.